Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% EV-to-EBITDA is 6.85 as of Aug. 03, 2026, which is 13% below its 10-year median of 7.90. The stock has 1 warning sign investors should review. Among 119 Medical Diagnostics & Research companies, Invitro International ranks better than 81.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Invitro International's enterprise value is $0.55 Mil.
Invitro International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.08 Mil. Therefore, Invitro International's EV-to-EBITDA for today is 6.85.
The historical rank and industry rank for Invitro International's EV-to-EBITDA or its related term are showing as below:
IVRO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.9 Med: 7.9 Max: 41.09
Current: 6.85
During the past 9 years, the highest EV-to-EBITDA of Invitro International was 41.09. The lowest was -20.90. And the median was 7.90.
IVRO's EV-to-EBITDA is ranked better than 81.51% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.06
vs IVRO: 6.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Invitro International (OTCPK:IVRO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Invitro International's PE Ratio (TTM) for today is calculated as:
Invitro International's share price for today is $0.0679.
Invitro International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Invitro International EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Invitro International's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Invitro International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Invitro International's EV-to-EBITDA falls into.
Invitro International's current Enterprise Value is $0.55 Mil.
Invitro International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a EV-to-EBITDA of 6.85 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Invitro International. This is 13% below median its historical median of 7.90. According to the industry distribution chart, Invitro International ranks #22 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 18.5%.
Is Invitro International's EV-to-EBITDA too high?
Invitro International's current EV-to-EBITDA of 6.85 is 13% below median its 10-year median of 7.90. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.06. Invitro International's value of 6.85 is 54.5% below this industry median. Based on the distribution chart, Invitro International ranks #22 out of 119 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Invitro International's EV-to-EBITDA compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #22 out of 119 companies for EV-to-EBITDA. This places Invitro International in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 15.06. Invitro International's value of 6.85 is 54.5% below this benchmark. While the company's 10-year median is 7.90 vs. the industry median of 15.06, Invitro International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.06, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current EV-to-EBITDA of 6.85 is 54.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Invitro International. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current EV-to-EBITDA is 6.85, which is 13% below median its own 10-year median of 7.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current EV-to-EBITDA is 6.85, which is 13% below median its 10-year median of 7.90 and 54.5% below the Medical Diagnostics & Research industry median of 15.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Invitro International (IVRO), the current EV-to-EBITDA is 6.85 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
